Anixa Biosciences

Company snapshot

Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. The Company's vaccine portfolio includes vaccines being deve

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Anixa Biosciences. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Anixa Biosciences.

1. Jun 5, 2026 Clinical update

   α-lactalbumin vaccine — Phase 1

2. Jun 5, 2026 Clinical update

   Follicle Stimulating Hormone Receptor T Cells — Phase 1

3. Sep 3, 2024 Patent grant

   Cysteine protease inhibitors and methods of use thereof

View all clinical trial activity →

• What is Anixa Biosciences?

  Anixa Biosciences is a pharma organization headquartered in San Jose, USA. It trades on NYSE under ticker ANIX. Primary therapeutic focus areas include Ovarian Cancer, Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer. NovaPharmaNews links 2 clinical program(s), 0 drug prof

• Is Anixa Biosciences publicly traded?

  Yes. Anixa Biosciences is listed with ticker ANIX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Anixa Biosciences develop or market?

  We link 4 drug profile(s) where Anixa Biosciences is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/anixa-biosciences-inc#company-drugs.

• What are the latest developments for Anixa Biosciences?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Anixa Biosciences focus on?

  Anixa Biosciences focuses on Ovarian Cancer, Pathologic Stage IIA-IIIC Triple-Negative Breast Cancer based on our analysis of their pipeline programs and drug development activities.